Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Synbiose-2 combination B-cell immunomodulation trial in severe systemic lupus erythematosus
2023-507867-20-00Phase 3Completed
- Sponsor
- Leiden University Medical Center
- Start
- Aug 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial of belimumab and rituximab in systemic lupus erythematosus (SLE) (2 arms), sponsored by Leiden University Medical Center. Primary endpoint: Treatment failure rate during the 2 years study period. Started Aug 2024; status: completed.
02
Drugs
belimumabrituximab
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on 2023-507867-20-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507867-20-00.